Synchron, a developer of brain-computer interface (BCI) technology, has acquired an equity stake in Germany-based medical technology company Acquandas.

Acquandas specialises in providing thin film components to the healthcare industry, particularly to medical device OEMs, and other industrial markets.

As part of the transaction, Synchron’s CEO and founder Tom Oxley will be appointed to the Acquandas Governance Council, and Synchron CTO Riki Banerjee as a board observer.

Oxley said: “As we pioneer functional endovascular neurotechnology, this investment strengthens our technology innovation and supply chain for our unique product offerings, beginning with brain-computer interfaces.”

Based in New York City, Synchron is a neurotechnology company that develops an endovascular BCI to restore brain functionality in patients with severe paralysis.

The clinical-stage company is developing a neuroprosthesis to restore motor signalling to control digital devices, helping individuals with motor impairment.

Established in 2012, Acquandas is developing an entirely new generation of metallic components, based on the advanced microsystem technology processes.

The company manufactures miniaturised structures, such as micro-patterned Nitinol thin films, with a high-structure resolution, high geometrical complexity, biocompatibility, and improved mechanical properties.

Acquandas has established an entirely new generation of shape-memory, flexible metallic components with applications in medical devices.

The German medical technology company’s capability to manufacture miniaturised structures will provide Synchron with a unique product offering in the implantable medical device industry.

Acquandas CEO and founder Rodrigo Lima de Miranda said: “After many years of development in fabrication technology, I am thrilled to welcome Synchron on board as an investor.

“This major investment will not only strengthen our existing partnership but will also play a pivotal role in expanding our facilities and capabilities. It serves as a testament to the readiness of our fabrication technology and our company for the market.”